Centogene N.V. (CNTG) Stock

About Centogene N.V.

Centogene N.V., along with its affiliates, operates globally with a primary focus on rare diseases. The company excels at converting diverse real-world data—spanning clinical, genetic, and other sources—into practical insights for patients, medical professionals, and pharmaceutical enterprises worldwide. Its activities are organized across three core divisions: Pharmaceutical, Diagnostics, and COVID-19 testing. At the heart of Centogene's strategy is its unique rare disease platform, a comprehensive repository of biological samples and integrated data. This platform consolidates epidemiological, phenotypic, and heterogenetic information, significantly improving the identification and ongoing surveillance of rare hereditary conditions. Furthermore, it plays a crucial role in accelerating the development of orphan drugs. The company provides an array of services within its Pharmaceutical segment, including target identification, early patient recruitment, epidemiological intelligence, biomarker discovery, and patient monitoring. Its Diagnostics arm offers genetic sequencing and diagnostic testing, reaching physicians, laboratories, and hospitals directly or through established distribution channels. Centogene also supplies COVID-19 testing solutions, covering both PCR and antigen tests. Established in 2006 and based in Rostock, Germany, Centogene N.V. holds key collaborative and licensing agreements with prominent partners such as Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation.

Centogene N.V. is headquartered in DE.

Centogene N.V. (CNTG) stock trades at $0.33 with a market capitalization of $9.42M. The stock is valued at a price-to-earnings (P/E) ratio of -0.22, price-to-book of -0.32, price-to-sales of 0.17. Over the past 52 weeks the stock has ranged between $0.33 and $0.43, and currently trades 23.3% below its 52-week high.

On profitability, Centogene N.V. generates a return on equity (ROE) of 397.65% — well above the market average, a sign of a high-quality business, return on capital employed of -87.78%, an operating margin of -61.11%, a net profit margin of -73.21%.

Official website: www.centogene.com